The role of B7-CD28 co-stimulation in tumor rejection

International Immunology

Volumn 10, Issue 6, 1998, Pages 791-797

  Yu, Xiang ^a   Abe, Ryo ^b   Modes, Richard J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

B7 1; B7 2; CD80; CD86; EL4

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; MUTANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR REJECTION;

AGE FACTORS; ANIMALS; ANTIGENS, CD28; ANTIGENS, CD80; CELL LINE; CLONING, MOLECULAR; FLOW CYTOMETRY; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; TIME FACTORS; TRANSFECTION;

EID: 0031839501     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/10.6.791     Document Type: Article

References (32)

1. Guerder, S. and Flavell, R. A. 1995. Co-stimulation in tolerance and autoimmunity. Int. Rev. Immunol. 13:135.
2. Chen, L., Linsley, P. S. and Hellstrom, K. E. 1993. Co-stimulation of T cells for tumor immunity. Immunol. Today 14:483.
3. Kaye, P.M. 1995. Co-stimulation and the regulation of antimicrobial immunity. Immunol. Today 16:423.
4. Bretscher, P. 1992 The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 13:74.
5. June, C. H., Bluestone, J. A., Nadler, L. M. and Thompson, C. B. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
6. Hathcock, K. S. and Modes, R. J. 1996. Role of the CD28-B7 co-stimulatory pathways in T cell-dependent B cell responses. Adv. Immunol. 62:131.
7. + T cells by B7-transfected melanoma cells [see comments]. Science 259:368.
8. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I. and Hellstrom, K. E. 1994. Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
9. Townsend, S. E., Su, F. W., Atherton, J. M. and Allison, J. P. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
10. Hodge, J. W., Abrams, S., Schlom, J. and Kantor, J. A. 1994. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 co-stimulatory molecules. Cancer Res. 54:5552.
11. Baskar, S., Clements, V. K., Glimcher, L. H., Nabavi, N. and Ostrand-Rosenberg, S. 1996. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 co-stimulatory molecules. J. Immunol. 156:3821.
12. La Motte, R. N., Rubin, M. A., Barr, E., Leiden, J. M., Bluestone, J. A. and Mokyr, M. B. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 co-stimulatory molecule. Cancer Immunol. Immunother. 42:161.
13. Matulonis, U., Dosiou, C., Freeman, G., Lamont, C., Mauch, P., Nadler, L. M. and Griffin, J. D. 1996. B7-1 is superior to B7-2 co-stimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
14. Gajewski, T. F., Fallarino, F., Uyttenhove, C. and Boon, T. 1996. Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
15. Greenfield, E. A., Howard, E., Paradis, T., Nguyen, K., Benazzo, F., McLean, P., Hollsberg, P., Davis, G., Hafler, D. A., Sharpe, A. H., Freeman, G. J. and Kuchroo, V. K. 1997. B7.2 expressed by T cells does not induce CD28-mediated co-stimulatory activity but retains CTLA-4 binding: implications for induction of antitumor immunity to T cell tumors. J. Immunol. 158:2025.
16. Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J. W., Kim, J., Goldberg, J. M., Hathcock, K. and Laszlo, G. 1993. Murine B7-2, an alter native CTLA-4 counter-receptor that co-stimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
17. Wu, Y., Guo, Y., Huang, A., Zheng P. and Liu, Y. 1997. CTLA-4-B7 interaction is sufficient to co-stimulate T cell clonal expansion. J. Exp. Med. 185:1327.
18. Shahinian, A., Pfeffer, K., Lee, K. P., Kundig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P. S., Thompson, C. B. and Mak, T. W. 1993. Differential T cell co-stimulatory requirements in CD28-deficient mice. Science 261:609.
19. Gunning, P., Leavitt, J., Muscat, G., Ng, S. Y. and Kedes, L. 1987. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl Acad. Sci. USA 84:4831.
20. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P. and Hodes, R. J. 1994. Comparative analysis of B7-1 and B7-2 co-stimulatory ligands: expression and function. J. Exp Med. 180:631.
21. Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A. and Peach, R. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [published erratum appears in Immunity 1995 2(2):following 203]. Immunity 1:793.
22. Ellis, J. H., Burden, M. N., Vinogradov, D. V., Linge, C. and Crowe, J. S. 1996. Interactions of CD80 and CD86 with CD28 and CTLA-4. J. Immunol. 156:2700.
23. Lenschow, D. J., Zeng, Y., Hathcock, K. S., Zuckerman, L. A., Freeman, G., Thistlethwaite, J. R., Gray, G. S., Hodes, R. J. and Bluestone, J. A. 1995. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 60:1171.
24. Kuchroo, V. K., Das, M. P., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N. and Glimcher, L. H. 1995. B7-1 and B7-2 co-stimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
25. Martin-Fontecha, A., Cavallo, F., Bellone, M., Heltai, S., Iezzi, G., Tornaghi, P., Nabavi, N., Forni, G., Dellabona, P. and Casorati, G. 1996. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur. J. Immunol. 26:1851.
26. van Dijk, A. M., Otten, H. G., Vercauteren, S. M., Kessler, F. L., De Boer, M., Verdonck, L. F. and de Gast, G. C. 1996. Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells. Eur. J. Immunol. 26:2275.
27. Krummel, M. F. and Allison, J. P. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation [see comments]. J. Exp. Med. 182:459.
28. Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B. and Bluestone, J. A. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
29. Geldhof, A. B., Moser, M., Lespagnard, L., Thielemans, K. and De Baetselier, P. 1998. Interleukin-12-activated natural killer cells recognize B7 co-stimulatory molecules on tumor cells and autologous dendritic cells. Blood 91:196.
30. Wu, T. C., Huang, A. Y., Jaffee, E. M., Levitsky, H. I. and Pardoll, D. M. 1995. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182:1415.
31. Chambers, B. J., Salcedo, M. and Ljunggren, H. G. 1996. Triggering of natural killer cells by the co-stimulatory molecule CD80 (B7-1). Immunity. 5:311.
32. Brunschwig, E. B., Levine, E., Trefzer, U. and Tykocinski, M. L. 1995. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain co-stimulator function. J. Immunol. 155:5498.